About
About
Oxford has invested in five existing life science buildings in the Navy Yard owned by Ensemble Real Estate Investments: 300, 351 and 400 Rouse Boulevard, and 4701 and 4751 League Island Boulevard, which are fully leased to industry-leading life science companies including Iovance Biotherapeutics, Adaptimmune Therapeutics PLC, and WuXi Advanced Therapies.
Oxford has invested in the first phase of the partnership’s two new development projects—1201 Normandy Place (a four story, 137,000 square foot lab building) and 333 Rouse Boulevard (a two story, 105,000 square foot lab and GMP building). Construction of both buildings will commence in 2022 on a speculative basis.
The Team
Oxford
Adam Frazier
Vice President - Head of New York
afrazier@oxfordproperties.com
646 376 3141
CBRE
Adam Frazier
Vice President - Head of New York
afrazier@oxfordproperties.com
646 376 3141
Oxford Properties Group
As a leading global real estate business, Oxford currently oversees more than 3 million SF of Life Sciences space across a mix of managed properties and development projects. We provide the platforms, amenities and services Life Sciences companies need to grow and prosper. Our fully integrated, global portfolio supports business at all stages of work in the sector, from early research and development through to production and manufacturing. In the US, Oxford’s Life Sciences portfolio is supported by expert on-the-ground presence in Boston, San Francisco, Washington DC and New York. Oxford is owned by OMERS, the defined benefit pension plan for over 500,000 of Ontario’s municipal employees with $90B in net assets.